Will direct thrombin inhibition change the boundaries of oral anti-coagulation?
Lomas
O
O
The John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK.
Argyle
R A
RA
Prendergast
B D
BD
D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D001384:Azetidines / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001596:Benzylamines / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D000069604:Dabigatran; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D013917:Thrombin / Q000037:antagonists & inhibitors*; D054556:Venous Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D001384:Azetidines; D001562:Benzimidazoles; D001596:Benzylamines; D011725:Pyridines; C426686:ximelagatran; D013917:Thrombin; D000069604:Dabigatran